2,073 results on '"Cephalosporins adverse effects"'
Search Results
2. Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions.
- Author
-
Lee EY, Gomes T, Drucker AM, Daneman N, Asaf A, Wu F, Piguet V, and Juurlink DN
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Administration, Oral, Case-Control Studies, Cephalosporins adverse effects, Cephalosporins administration & dosage, Emergency Service, Hospital statistics & numerical data, Fluoroquinolones administration & dosage, Fluoroquinolones adverse effects, Hospitalization statistics & numerical data, Nitrofurantoin administration & dosage, Nitrofurantoin adverse effects, Ontario epidemiology, Penicillins administration & dosage, Penicillins adverse effects, Sulfonamides administration & dosage, Sulfonamides adverse effects, Risk Assessment statistics & numerical data, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents administration & dosage, Drug Eruptions etiology, Drug Eruptions epidemiology, Macrolides administration & dosage, Macrolides adverse effects
- Abstract
Importance: Serious cutaneous adverse drug reactions (cADRs) are potentially life-threatening drug hypersensitivity reactions involving the skin and internal organs. Antibiotics are a recognized cause of these reactions, but no studies have compared relative risks across antibiotic classes., Objectives: To explore the risk of serious cADRs associated with commonly prescribed oral antibiotics, and to characterize outcomes of patients hospitalized for them., Design, Setting, and Participants: Nested case-control study using population-based linked administrative datasets among adults aged 66 years or older who received at least 1 oral antibiotic between 2002 and 2022 in Ontario, Canada. Cases were those who had an emergency department (ED) visit or hospitalization for serious cADRs within 60 days of the prescription, and each case was matched with up to 4 controls who did not., Exposure: Various classes of oral antibiotics., Main Outcomes and Measures: Conditional logistic regression estimate of the association between different classes of oral antibiotics and serious cADRs, using macrolides as the reference group., Results: During the 20-year study period, we identified 21 758 older adults (median age, 75 years; 64.1% female) who had an ED visit or hospitalization for serious cADRs following antibiotic therapy and 87 025 matched controls who did not. In the primary analysis, sulfonamide antibiotics (adjusted odds ratio [aOR], 2.9; 95% CI, 2.7-3.1) and cephalosporins (aOR, 2.6; 95% CI, 2.5-2.8) were most strongly associated with serious cADRs relative to macrolides. Additional associations were evident with nitrofurantoin (aOR, 2.2; 95% CI, 2.1-2.4), penicillins (aOR, 1.4; 95% CI, 1.3-1.5), and fluoroquinolones (aOR, 1.3; 95% CI, 1.2-1.4). The crude rate of ED visits or hospitalization for cADRs was highest for cephalosporins (4.92 per 1000 prescriptions; 95% CI, 4.86-4.99) and sulfonamide antibiotics (3.22 per 1000 prescriptions; 95% CI, 3.15-3.28). Among the 2852 case patients hospitalized for cADRs, the median length of stay was 6 days (IQR, 3-13 days), 9.6% required transfer to a critical care unit, and 5.3% died in the hospital., Conclusion and Relevance: Commonly prescribed oral antibiotics are associated with an increased risk of serious cADRs compared with macrolides, with sulfonamides and cephalosporins carrying the highest risk. Prescribers should preferentially use lower-risk antibiotics when clinically appropriate.
- Published
- 2024
- Full Text
- View/download PDF
3. Waveform Window #57: Cefepime Neurotoxicity in EEG.
- Author
-
Shugan A
- Subjects
- Humans, Male, Cephalosporins adverse effects, Female, Cefepime adverse effects, Electroencephalography drug effects, Anti-Bacterial Agents adverse effects, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes physiopathology
- Published
- 2024
- Full Text
- View/download PDF
4. Ceftobiprole Medocaril Sodium.
- Author
-
Beninger P
- Subjects
- Humans, Cephalosporins adverse effects, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents administration & dosage
- Abstract
Competing Interests: Declaration of competing interest None.
- Published
- 2024
- Full Text
- View/download PDF
5. Association of HLA alleles with cephalosporin allergy in the Taiwanese population.
- Author
-
Wang CC, Shen CH, Lin GC, Chen YM, and Chen IC
- Subjects
- Humans, Taiwan epidemiology, Male, Female, Middle Aged, Case-Control Studies, Retrospective Studies, HLA Antigens genetics, Adult, Aged, Genotype, Genetic Predisposition to Disease, Anti-Bacterial Agents adverse effects, Cephalosporins adverse effects, Alleles, Drug Hypersensitivity genetics, Drug Hypersensitivity epidemiology
- Abstract
Cephalosporin antibiotics are widely used in clinical settings, but they can cause hypersensitivity reactions, which may be influenced by genetic factors such as the expression of Human leukocyte antigen (HLA) molecules. This study aimed to investigate whether specific HLA alleles were associated with an increased risk of adverse reactions to cephalosporins among individuals in the Taiwanese population. This retrospective case-control study analyzed data from the Taiwan Precision Medicine Initiative (TPMI) on 27,933 individuals who received cephalosporin exposure and had HLA allele genotyping information available. Using logistic regression analyses, we examined the associations between HLA genotypes, comorbidities, allergy risk, and severity. Among the study population, 278 individuals had cephalosporin allergy and 2780 were in the control group. Our results indicated that certain HLA alleles, including HLA-B*55:02 (OR = 1.76, 95% CI 1.18-2.61, p = 0.005), HLA-C*01:02 (OR = 1.36, 95% CI 1.05-1.77, p = 0.018), and HLA-DQB1*06:09 (OR = 2.58, 95% CI 1.62-4.12, p < 0.001), were significantly associated with an increased risk of cephalosporin allergy reactions. Additionally, the HLA-C*01:02 allele genotype was significantly associated with a higher risk of severe allergy (OR = 2.33, 95% CI 1.05-5.15, p = 0.04). This study identified significant associations between HLA alleles and an increased risk of cephalosporin allergy, which can aid in early detection and prediction of adverse drug reactions to cephalosporins. Furthermore, our study highlights the importance of HLA typing in drug safety and expanding our knowledge of drug hypersensitivity syndromes., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
6. Cefepime/enmetazobactam (Exblifep) for complicated urinary tract infections.
- Subjects
- Humans, Drug Combinations, Thiazoles adverse effects, Thiazoles therapeutic use, Thiazoles administration & dosage, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology, Cephalosporins adverse effects, Cephalosporins therapeutic use, Cefepime administration & dosage, Cefepime adverse effects, Cefepime therapeutic use, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
7. Ceftaroline for Central Nervous System Infections: Case Report of a Young Infant, and Scoping Review.
- Author
-
Urbach H, Sileo N, Lerma S, Nguyen K, Sosa Soto G, Nielsen M, Heiderich A, Holsapple J, Vuppula S, and Campbell JI
- Subjects
- Humans, Infant, Staphylococcus epidermidis drug effects, Vancomycin therapeutic use, Vancomycin adverse effects, Male, Cerebral Ventriculitis drug therapy, Cerebral Ventriculitis microbiology, Central Nervous System Infections drug therapy, Central Nervous System Infections microbiology, Rifampin therapeutic use, Rifampin adverse effects, Ceftaroline, Cephalosporins therapeutic use, Cephalosporins adverse effects, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents pharmacology, Staphylococcal Infections drug therapy, Staphylococcal Infections microbiology
- Abstract
Background: Managing health care acquired and device-associated intracranial infections in young children can be challenging given adverse antibiotic side effects and difficulties in achieving adequate central nervous system (CNS) antibiotic concentrations. Ceftaroline is a cephalosporin with a favorable safety profile and activity against methicillin-resistant Staphylococci and several Gram-negative organisms. Published data on the use of ceftaroline for CNS infections in children and adults are limited., Methods: We describe a 2-month-old infant with ventriculo-subgaleal shunt-associated methicillin-resistant Staphylococcus epidermidis ventriculitis, which was successfully treated with ceftaroline, in addition to vancomycin and rifampin. We conducted a scoping review of English-language literature retrieved from PubMed, EMBASE and Web of Science that assessed the use of ceftaroline for CNS infections., Results: We identified 22 articles for inclusion in our review, which described 92 unique patients, of whom 2 were <21 years old. Ceftaroline was commonly used in conjunction with other antibiotics to treat infections caused by Staphylococcus aureus , coagulase-negative Staphylococci and Streptococcus pneumoniae . Most case reports described clinical success with ceftaroline, though small case series and cohort studies yielded mixed efficacy assessments. Adverse effects attributed to ceftaroline were rare and included reversible myelosuppression, eosinophilia, hepatotoxicity and nephrotoxicity. Pharmacokinetic/pharmacodynamic studies suggested similar CNS penetration through inflamed meninges as other beta lactam antibiotics., Conclusions: We identified a growing body of published evidence supporting the use of ceftaroline in combination with other agents for the treatment of CNS infections. In absence of clinical trials, additional real-world data are needed to define the efficacy and safety of ceftaroline for children and adults with CNS infections., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Ceftobiprole mono-therapy versus combination or non-combination regimen of standard antibiotics for the treatment of complicated infections: A systematic review and meta-analysis.
- Author
-
Jame W, Basgut B, and Abdi A
- Subjects
- Humans, Randomized Controlled Trials as Topic, Bacterial Infections drug therapy, Bacterial Infections microbiology, Treatment Outcome, Gram-Negative Bacteria drug effects, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Cephalosporins therapeutic use, Cephalosporins administration & dosage, Cephalosporins adverse effects, Drug Therapy, Combination
- Abstract
Objective: Various bacteria produce complicated infections that are difficult to treat worldwide. Ceftobiprole is effective against resistant Gram-positive and Gram-negative bacteria., Methods: This review assessed effectiveness and safety of ceftobiprole monotherapy for severe infections. A systematic review and meta-analysis of randomized controlled trials comparing clinical cure, microbiological cure, and safety of ceftobiprole alone to a combination or non-combination antibiotic regimen was conducted. Until December 20, 2022, we searched a major databases., Results: This study includes 4168 patients from six trials. Ceftobiprole and comparator-received patients had similar clinical responses for all patient population. Also, the eradication rate of all organisms and specific pathogenic bacteria in microbiologically examined patients was comparable between the groups. Ceftobiprole induced more gastrointestinal side events than comparable drugs, mostly nausea [OR 1.91 (1.26-2.90), p=<0.01]. While skin-related adverse events were significantly associated with comparator antibiotics [6 trials, 4062 patients; OR 0.77 (0.60-0.99), p=0.03]., Conclusion: Ceftobiprole monotherapy is effective and safe for severe infections caused by Gram-positive or Gram-negative bacteria., Competing Interests: Declaration of competing interest The authors declare no conflicts of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Cefdinir Stool.
- Author
-
D'Agrosa A, Rajeev B, and Shank E
- Subjects
- Humans, Cephalosporins adverse effects, Male, Female, Child, Anti-Bacterial Agents adverse effects, Cefdinir, Feces chemistry
- Abstract
Competing Interests: Declaration of Competing Interest The authors report no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
10. Cephalosporin Allergy: Updates on Diagnostic Testing.
- Author
-
Chow TG, Brunner ES, and Khan DA
- Subjects
- Humans, Cross Reactions immunology, Diagnostic Tests, Routine, Cephalosporins adverse effects, Cephalosporins immunology, Drug Hypersensitivity diagnosis, Drug Hypersensitivity immunology, Skin Tests, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents immunology
- Abstract
Purpose of Review: Cephalosporins are one of the most prescribed antibiotics worldwide and are implicated in a wide range of hypersensitivity reactions (HSR). This review summarizes recent updates in cephalosporin hypersensitivity with a focus on diagnostic testing., Recent Findings: Reported testing strategies to evaluate different immediate and delayed cephalosporin HSR have included skin testing, in vitro testing, and diagnostic drug challenges. However, the diagnostic performance of in vivo and in vitro tests remains unclear across different hypersensitivity endotypes; adequately powered studies investigating the true positive and negative predictive value of these diagnostic modalities are needed using the reference standard of drug challenges to define cephalosporin hypersensitivity. Refinement of diagnostic testing should be guided by growth in our understanding of cephalosporin antigenic determinants. This growth will be crucial in driving further clarification of cross-reactivity between cephalosporins, and potentially delineating streamlined evaluation processes resulting in reduced unnecessary antibiotic avoidance., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
11. Are Cephalosporins Safe for Surgical Prophylaxis in Patients with Penicillin Allergy?
- Author
-
Abraham-Aggarwal K and Kacker A
- Subjects
- Humans, Cefazolin therapeutic use, Cefazolin adverse effects, Drug Hypersensitivity prevention & control, Penicillins adverse effects, Antibiotic Prophylaxis methods, Antibiotic Prophylaxis adverse effects, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Cephalosporins therapeutic use, Cephalosporins adverse effects, Surgical Wound Infection prevention & control
- Abstract
Cefazolin, also known as Ancef, is a first-generation cephalosporin antibiotic often used in surgery to treat or prevent bacterial infection of the surgical site. Ancef is safe for most of the population; however, many physicians use alternative, less effective medications in patients with penicillin allergy due to a fear of cross-reactivity between Ancef and one's penicillin allergy. In this article, we aim to examine if cefazolin is safe for patients with penicillin allergy., (© 2023 The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
12. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
- Author
-
Lanini S, Cai T, and Tascini C
- Subjects
- Aged, Female, Humans, Male, Cephalosporins therapeutic use, Cephalosporins adverse effects, Clinical Trials, Phase III as Topic, Drug Resistance, Bacterial, Enterobacteriaceae, Meropenem therapeutic use, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Cefepime therapeutic use, Enterobacteriaceae Infections drug therapy, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology
- Published
- 2024
- Full Text
- View/download PDF
13. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
- Author
-
van Os W and Zeitlinger M
- Subjects
- Aged, Female, Humans, Male, Cephalosporins therapeutic use, Cephalosporins adverse effects, Clinical Trials, Phase III as Topic, Meropenem therapeutic use, Enterobacteriaceae, Drug Resistance, Bacterial, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Cefepime therapeutic use, Urinary Tract Infections complications, Urinary Tract Infections drug therapy, Enterobacteriaceae Infections drug therapy
- Published
- 2024
- Full Text
- View/download PDF
14. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
- Author
-
Manesh A, Varghese GM, and Paterson DL
- Subjects
- Aged, Female, Humans, Male, Cephalosporins therapeutic use, Cephalosporins adverse effects, Clinical Trials, Phase III as Topic, Drug Resistance, Bacterial, Meropenem adverse effects, Meropenem therapeutic use, Microbial Sensitivity Tests, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Cefepime therapeutic use, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology
- Published
- 2024
- Full Text
- View/download PDF
15. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Reply.
- Author
-
Wagenlehner FM, McGovern PC, and Moeck G
- Subjects
- Humans, Cephalosporins therapeutic use, Cephalosporins adverse effects, Clinical Trials, Phase III as Topic, Drug Resistance, Bacterial, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Cefepime adverse effects, Cefepime therapeutic use, Urinary Tract Infections complications, Urinary Tract Infections drug therapy
- Published
- 2024
- Full Text
- View/download PDF
16. Unraveling cephalosporin-associated anaphylaxis: A comprehensive analysis using FDA Adverse Event Reporting System data.
- Author
-
Shah D, Rukasin C, Wang C, Phillips E, and Stone C
- Subjects
- Humans, United States epidemiology, Male, Adult, Female, Middle Aged, Adolescent, Aged, Child, Young Adult, Anti-Bacterial Agents adverse effects, Child, Preschool, Infant, Anaphylaxis epidemiology, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems statistics & numerical data, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Cephalosporins adverse effects
- Published
- 2024
- Full Text
- View/download PDF
17. Removing penicillin allergy label in a hospitalized adolescent with a remote penicillin and recent cephalosporin allergy.
- Author
-
Mari DC and Banks TA
- Subjects
- Humans, Male, Adolescent, Drug Labeling, Allergens immunology, Hospitalization, Cefepime adverse effects, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology, Penicillins adverse effects, Anti-Bacterial Agents adverse effects, Cephalosporins adverse effects
- Abstract
Background: β-Lactam antibiotics are widely used with increased utilization in hospitalized patients. Of this population, as high as 10-20% report an allergy to β-lactam antibiotics but <5% are at risk of developing clinically significant immunoglobulin E- or T-lymphocyte-mediated reactions. Most of the time, these reported allergies are present during an illness with no previous inquiry of their validity, which makes investigation and possible removal of this allergy label a challenge. Methods: We report a 16-year-old boy who presented with 1 week of night sweats, chills, headaches, and fatigue, followed by 1 day of fever and right knee swelling and who was diagnosed with septic bursitis. Due to concern of a penicillin allergy label, the patient was started on a cefepime infusion. Five minutes into the infusion, the patient reported puffy eyes and itchy throat, followed by a witnessed cascading flat nonpruritic erythematous rash from head to shoulders. This rash went away in 3 minutes after stopping the infusion and the patient being given 50 mg of intravenous diphenhydramine and 10 mg of oral dexamethasone. He was subsequently diagnosed with a cefepime allergy. Results: Allergy/immunology was the speciality consulted, and, by using a screening questionnaire, the patient's reported penicillin allergy was determined to be low risk. Subsequent 1-step oral challenge was the key to providing the patient with the necessary antibiotic course to resolve his infection. Conclusion: Multiple reported antibiotic allergies lead to poor antibiotic stewardship that causes impactful health and financial burden on the patient and health-care system. It is thus important to have an evidence-based systematic approach to de-label penicillin antibiotic allergy labels to reduce these potential harms.
- Published
- 2024
- Full Text
- View/download PDF
18. Immunogenicity of cephalosporin components in non-IgE-mediated cephalosporin allergy.
- Author
-
Tuesuwan B, Buranapraditkun S, Arjharn W, Suthumchai N, Chongpison Y, and Klaewsongkram J
- Subjects
- Humans, Cephalosporins adverse effects, Anti-Bacterial Agents, Penicillins, Monobactams, Cross Reactions, Skin Tests, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology, Drug Hypersensitivity drug therapy, Hypersensitivity drug therapy
- Published
- 2024
- Full Text
- View/download PDF
19. Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections.
- Author
-
Herrmann J, Burgener-Gasser AV, Goldenberger D, Roth J, Weisser M, Tamma PD, and Tschudin-Sutter S
- Subjects
- Humans, Cefepime adverse effects, Anti-Bacterial Agents adverse effects, Carbapenems adverse effects, Cephalosporins adverse effects, Retrospective Studies, Hospital Mortality, beta-Lactamases, Microbial Sensitivity Tests, Enterobacteriaceae Infections drug therapy, Enterobacteriaceae Infections microbiology, Sepsis drug therapy, Gammaproteobacteria, Bacterial Proteins
- Abstract
Purpose: Cefepime is recommended for treating infections caused by AmpC beta-lactamase-producing Enterobacterales (AmpC-PE), though supporting evidence is limited. Therefore, this study compared outcomes associated with cefepime versus carbapenem therapy for bloodstream infections (BSIs) caused by AmpC-PE after phenotypic exclusion of ESBL-co-producing isolates., Methods: This retrospective cohort study compared definite cefepime versus carbapenem treatment for AmpC-PE BSI in hospitalized patients of the University Hospital Basel, Switzerland, between 01/2015 and 07/2020. Primary outcomes included in-hospital death, renal impairment and neurologic adverse events; secondary outcomes included length of hospital stay and recurrent infection., Results: Two hundred and seventy episodes of AmpC-PE BSI were included, 162, 77 and 31 were treated with a carbapenem, cefepime and other antibiotics, respectively. Patients treated with carbapenems were more likely to be transferred to the ICU on admission and more frequently had central venous catheter as a source of infection. In uni- and multivariable analyses, primary and secondary outcomes did not differ between the two treatment groups, except for more frequent occurrence of neurological adverse events among patients treated with carbapenems and shorter length of hospital stay among survivors treated with cefepime., Conclusion: After excluding isolates with phenotypic ESBL-co-production, cefepime was not associated with adverse outcomes compared to carbapenems when used to treat BSIs caused by AmpC-PE. Our study provides evidence to support the use of cefepime as a safe treatment strategy for AmpC-PE BSI, particularly in clinically stable patients without initial renal impairment or increased susceptibility to neurological adverse events., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
20. Bacterial Isolates and Characteristics of Children With Febrile Neutropenia on Treatment for Cancer at a Tertiary Hospital in Western Kenya.
- Author
-
Kipchumba SK, Njuguna FM, and Nyandiko WM
- Subjects
- Male, Child, Humans, Female, Anti-Bacterial Agents adverse effects, Tertiary Care Centers, Cross-Sectional Studies, Kenya, Cephalosporins adverse effects, Bacteremia complications, Bacteremia drug therapy, Bacteremia microbiology, Hematologic Neoplasms complications, Hematologic Neoplasms drug therapy, Hematologic Neoplasms microbiology, Febrile Neutropenia drug therapy, Febrile Neutropenia epidemiology, Febrile Neutropenia complications, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute drug therapy
- Abstract
Purpose: This study aimed to identify the patient characteristics of children with febrile neutropenia, the associated bacterial organisms, and their sensitivity patterns., Materials and Methods: A descriptive cross-sectional study was conducted at the Moi Teaching and Referral Hospital (MTRH) pediatric oncology ward, from June 2021 to April 2022. A total of 110 children who developed fever and neutropenia during chemotherapy were enrolled. Blood samples for culture were collected aseptically. Patient characteristics were presented in frequency tables. Antimicrobial sensitivity patterns were plotted in tables against the bacterial isolates cultured. Chi-square/Fisher's exact test was used to determine any association between patient characteristics, bacterial growth, and antimicrobial sensitivity., Results: The majority (n = 66; 60%) were males. The median age was 6.3 years (standard deviation, 3.7). The majority of patients 71 (64.5%) had hematologic malignancies, the most common being AML. There was a significant association between severity of neutropenia and hematologic malignancies ( P = .028). In total, 31/110 (28.2%) blood cultures were positive for bacterial growth. Gram-positive bacteria were more frequent (n = 20; 58.1%). The most common organism was Escherichia coli (n = 6; 18.2%), followed by Staphylococcus aureus (n = 5; 15.2%). All the isolates were sensitive to linezolid and vancomycin and also showed good sensitivity toward meropenem (n = 10/11; 90.9%). High resistance to cephalosporins was noted with ceftriaxone (n = 5/6; 83.3%), cefepime (n = 4/7; 57.1%), and ceftazidime (n = 3/4; 75%)., Conclusion: The most common malignancy associated with febrile neutropenia was AML. Gram-positive bacteria were the most common isolates. There was high resistance to cephalosporins.
- Published
- 2024
- Full Text
- View/download PDF
21. Ceftriaxone-induced encephalopathy in a patient with a normal renal function.
- Author
-
Zarauskas A, Rodrigues B, and Alvarez V
- Subjects
- Female, Humans, Anti-Bacterial Agents adverse effects, Cephalosporins adverse effects, Kidney, Ceftriaxone adverse effects, Brain Diseases chemically induced, Brain Diseases drug therapy
- Abstract
Ceftriaxone-induced encephalopathy is an exceptionally rare adverse effect of this commonly used cephalosporin and is generally observed in patients undergoing haemodialysis or suffering from severe renal failure. We present a case of a fit woman in her mid-80s with a normal renal function who developed severe fluctuating neurological symptoms (aphasia, loss of contact, chorea-like tongue movements) while being treated with ceftriaxone for a urinary tract infection with bacteraemia. The symptoms began on day 4 of treatment and an adverse drug reaction was suspected on day 7, after exhaustive investigations failed to reveal another cause. A complete recovery was observed 3 days after discontinuing ceftriaxone. Our case highlights the need to consider the diagnosis of ceftriaxone encephalopathy, even if the traditional risk factors are lacking. In this article, we also provide a brief overview of the pathophysiology as well as a literature review concerning the subject., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
22. Assessment of the Safety of Exposure to Cefcapene Pivoxil during the First Trimester of Pregnancy: A Prospective Cohort Study in Japan.
- Author
-
Miki Y, Koga Y, Taogoshi T, Itamura R, Yokooji T, Hishinuma K, Yakuwa N, Goto M, Murashima A, and Matsuo H
- Subjects
- Humans, Female, Pregnancy, Japan epidemiology, Adult, Prospective Studies, Infant, Newborn, Abnormalities, Drug-Induced epidemiology, Abnormalities, Drug-Induced etiology, Incidence, Young Adult, Pregnancy Trimester, First, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents administration & dosage, Cephalosporins adverse effects
- Abstract
Cefcapene pivoxil hydrochloride is an antibiotic often used by women who are or may be pregnant. However, the safety of exposure to it during the first trimester of pregnancy has not been assessed. In this study, we aimed to clarify the effects of exposure during the first trimester of pregnancy on maternal and fetal outcomes. Data were obtained from pregnant women who were counseled on drug use during pregnancy at two Japanese facilities from April 1988 to December 2017. The incidence of major malformations in singleton pregnancy was compared between neonates born to women who took cefcapene pivoxil hydrochloride (n = 270) and control drugs (n = 1594) during their first trimester. The adjusted odds ratio of the incidence of major malformations was calculated using multivariate logistic regression analysis adjusted for smoking during pregnancy and maternal age. The incidence of major malformations was 2.6% in the cefcapene pivoxil hydrochloride group and 1.8% in the control group. There were no significant differences in the incidence between the cefcapene pivoxil hydrochloride and control groups (adjusted odds ratio: 1.48 [95% confidence interval: 0.64-3.42], p = 0.36). This prospective cohort study showed that exposure to cefcapene pivoxil hydrochloride during the first trimester of pregnancy was not associated with increased risk of major malformations in infants. Our findings will help healthcare providers in choosing appropriate medicines.
- Published
- 2024
- Full Text
- View/download PDF
23. Cefepime Neurotoxicity in Patients With Normal Renal Function: An Overlooked Cause of Encephalopathy in the Intensive Care Unit.
- Author
-
Alagha Z, Crow S, Abdeen AMZ, Alastal M, and Alastal A
- Subjects
- Humans, Aged, Female, Cephalosporins adverse effects, Cefepime adverse effects, Anti-Bacterial Agents adverse effects, Intensive Care Units, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes diagnosis, Brain Diseases chemically induced
- Abstract
Cefepime is a fourth-generation cephalosporin with extended antimicrobial coverage. Concerns have been raised about the side effects of cefepime including myoclonus, encephalopathy, and seizures, especially when renal impairment is present. There have been reports of cases of adverse neurological consequences despite appropriate renal adjustment. Here, we present a case of a 69-year-old patient initially diagnosed with pneumonia and treated with cefepime. The patient later developed altered mental status, leading to differential diagnoses including stroke, drug overdose, or non-convulsive seizures. Following a comprehensive workup, it was determined that she had cefepime-induced encephalopathy, despite having normal kidney function, which resolved completely after discontinuing the medication. In addition, we include similar cases retrieved from PubMed up to the present date, to the best of our knowledge., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
24. Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future.
- Author
-
Bavaro DF, Belati A, Bussini L, Cento V, Diella L, Gatti M, Saracino A, Pea F, Viale P, and Bartoletti M
- Subjects
- Humans, Cephalosporins adverse effects, Anti-Bacterial Agents adverse effects, Ceftaroline, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections drug therapy, Bacteremia drug therapy, Endocarditis drug therapy
- Abstract
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) is a major issue in healthcare, since it is often associated with endocarditis or deep site foci. Relevant morbidity and mortality associated with MRSA-BSIs forced the development of new antibiotic strategies; in particular, this review will focus the attention on fifth-generation cephalosporins (ceftaroline/ceftobiprole), that are the only ß-lactams active against MRSA., Areas Covered: The review discusses the available randomized controlled trials and real-world observational studies conducted on safety and effectiveness of ceftaroline/ceftobiprole for the treatment of MRSA-BSIs. Finally, a proposal of MRSA-BSI treatment flowchart, based on fifth-generation cephalosporins, is described., Expert Opinion: The use of anti-MRSA cephalosporins is an acceptable choice either in monotherapy or combination therapy for the treatment of MRSA-BSIs due to their relevant effectiveness and safety. Particularly, their use may be advisable in combination therapy in case of severe infections (including endocarditis or persistent bacteriemia) or in monotherapy in subjects at higher risk of drugs-induced toxicity with older regimens. On the contrary, caution should be taken in case of suspected/ascertained central nervous system infections due to inconsistent data regarding penetration of these drugs in cerebrospinal fluid and brain tissues.
- Published
- 2024
- Full Text
- View/download PDF
25. Assessing Pediatric Cephalosporin Allergic Reactions Through Direct Graded Oral Challenges.
- Author
-
Sillcox C, Gabrielli S, O'Keefe A, McCusker C, Abrams EM, Eiwegger T, Atkinson A, Kim V, Copaescu AM, and Ben-Shoshan M
- Subjects
- Male, Humans, Child, Child, Preschool, Female, Cephalosporins adverse effects, Skin Tests adverse effects, Canada epidemiology, Anti-Bacterial Agents adverse effects, Monobactams, Penicillins adverse effects, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Drug Hypersensitivity etiology, Hypersensitivity complications
- Abstract
Background: Cephalosporins, β-lactam antibiotics, commonly cause allergic reactions., Objective: To assess the clinical characteristics and management of pediatric patients with suspected cephalosporin allergy using direct graded oral challenges (GOCs)., Methods: Children referred for suspected cephalosporin allergy at 4 Canadian clinics were recruited over 10 years. Data on demographics, clinical reaction characteristics, and management were collected through a questionnaire. Patients underwent a direct GOC (initially 10% of the treatment dose, then 90% after 20 min), and reactions were monitored 1 week postchallenge. Families were contacted annually for up to 5 years to detect subsequent antibiotic reactions. Logistic regression analysis identified factors associated with positive GOC reactions., Results: Among the 136 patients reporting cephalosporin allergy, 75 (55.1%) were males with a median age of 3.9 years (interquartile range 2.3-8.7). Cefprozil represented the most common cephalosporin linked to the index reaction (67.6% of cases). Of the 136 direct GOCs, 5.1% had an immediate and 4.4% a nonimmediate reaction, respectively. Positive GOCs conducted in children with a history of skin-limited nonsevere rashes were classified as mild, benign skin rashes. Positive GOCs were more likely in children with food allergies (adjusted odds ratio 1.14; 95% confidence interval [95% CI] 1.00-1.29)., Conclusions: Direct GOCs are safe and effective for diagnosing pediatric cases that report nonvesicular skin-limited symptoms while being treated with cephalosporins., (Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Building the Evidence Base for Safe Direct Cephalosporin Challenges.
- Author
-
Norton AE, Koo G, and Stone CA Jr
- Subjects
- Humans, Cephalosporins adverse effects, Monobactams
- Published
- 2024
- Full Text
- View/download PDF
27. Cefiderocol-associated brown chromaturia.
- Author
-
Smith M and Foong KS
- Subjects
- Female, Humans, Anti-Bacterial Agents adverse effects, Cephalosporins adverse effects, Microbial Sensitivity Tests, Drug Resistance, Multiple, Bacterial, Cefiderocol, Pseudomonas Infections drug therapy
- Abstract
Cefiderocol is a novel siderophore cephalosporin antibiotic. In the present case report, a woman in her 70s presented with a 1-week history of altered mental status and progressive purulent discharge from a non-healing diabetic foot ulcer on her right heel. MRI of the right foot revealed chronic osteomyelitis of the calcaneum. Surgical debridement was performed, and the tissue cultures grew extensively drug resistant (XDR) Pseudomonas aeruginosa , XDR Acinetobacter baumannii and Enterococcus faecalis The patient received ampicillin-sulbactam and cefiderocol. The antibiotic treatment course was complicated by brown urine discolouration. Investigations were unrevealing for haemoglobinuria, myoglobinuria and bilirubinuria. A side effect from cefiderocol was suspected and subsequently discontinued. Her urine colour returned to its normal colour within 3 days of discontinuation of cefiderocol., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
28. Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria.
- Author
-
Fresán D, Luque S, Benítez-Cano A, Sorlí L, Montero MM, De-Antonio M, Vega V, Roberts JA, Horcajada JP, and Grau S
- Subjects
- Humans, Male, Aged, Aged, 80 and over, Female, Cephalosporins adverse effects, Infusions, Parenteral, Monobactams, Ceftaroline, Anti-Bacterial Agents adverse effects, Drug Monitoring methods
- Abstract
Background: Ceftaroline is a novel cephalosporin active against MDR Gram-positive (GP) bacteria. For β-lactam antibiotics, such as ceftaroline, prolonged infusions and therapeutic drug monitoring (TDM) are used for dosage optimization based on their pharmacokinetics/pharmacodynamics (PK/PD)., Objectives: To describe our experience with TDM and PK/PD target attainment of ceftaroline administered by intermittent and prolonged infusion in a cohort of patients with MDR-GP bacterial infections., Methods: Patients treated with ceftaroline administered by continuous (24 h), extended (3 h/6 h) and intermittent infusion (1 h) and undergoing TDM of plasma concentrations were included. A 100%fT>4×MIC was the pre-specified PK/PD target and 100%fT>10×MIC was considered overexposure. Dose recommendations were made based on TDM results and each patient's clinical condition., Results: Twelve patients [83.3% male, median age of 73 (38-83) years] were included. Nine patients (75%) achieved 100%fT>4×MIC, all under prolonged infusions. In one patient, the 100%fT was >10×MIC but no toxicity was observed. Based on TDM results, initial doses were recommended to be maintained in eight patients, decreased in three and increased in one., Conclusions: The administration of ceftaroline by prolonged infusion together with TDM may be a useful strategy for achieving the desired PK/PD target in these patients. However, more studies evaluating the relationship between PK/PD attainment and clinical outcomes are needed., (© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
29. Piperacillin-Tazobactam Versus Anti-Pseudomonal Cephalosporins and Renal and Neurologic Outcomes in Critically Ill Adults: A Secondary Analysis of the SMART Trial.
- Author
-
Qian ET, Wang L, Stollings JL, Casey JD, Rice TW, and Semler MW
- Subjects
- Adult, Humans, Acute Kidney Injury etiology, Anti-Bacterial Agents adverse effects, Coma chemically induced, Coma drug therapy, Delirium etiology, Drug Therapy, Combination, Clinical Trials as Topic, Cephalosporins adverse effects, Critical Illness therapy, Piperacillin, Tazobactam Drug Combination adverse effects
- Abstract
Background: Prior studies suggest associations between receipt of piperacillin-tazobactam and development of acute kidney injury and receipt of anti-pseudomonal cephalosporins and neurotoxicity. We compared clinically-relevant renal and neurologic outcomes in critically ill patients who received piperacillin-tazobactam versus anti-pseudomonal cephalosporins. Methods: We conducted a secondary analysis of data from the Isotonic Solutions and Major Adverse Renal Events Trial examining patients who received piperacillin-tazobactam or an anti-pseudomonal cephalosporin within 24 h of intensive care unit admission. We performed multivariable analysis using a proportional odds model to examine the association between the first antibiotic received and the outcomes of Major Adverse Kidney Events within 30 days (MAKE30) and days alive and free of delirium and coma to day 28. Results: 3199 were included in the study; 2375 (74%) receiving piperacillin-tazobactam and 824 (26%) receiving anti-pseudomonal cephalosporin. After adjustment for prespecified confounders, initial receipt of piperacillin-tazobactam, compared to anti-pseudomonal cephalosporins, was not associated with higher incidence of MAKE30 (adjusted odds ratio, 1.03; 95% CI, 0.83-1.27; P = .80) but was associated with a greater number of days alive and free of delirium and coma (adjusted odds ratio, 1.18; 95% CI, 1.00-1.38; P = .04). In a sensitivity analysis adjusting for baseline receipt of medications which may impact neuro function, this finding was not significant. Conclusion: Among critically ill adults, receipt of piperacillin-tazobactam was not associated with an increased incidence of death, renal replacement therapy, or persistent renal dysfunction or a greater number of days alive and free of delirium and coma. Randomized trials are needed to inform the choice of antibiotics for empiric treatment infection in critically ill adults., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2023
- Full Text
- View/download PDF
30. Different antibiotic treatments for group A streptococcal pharyngitis.
- Author
-
Hedin K, Thorning S, and van Driel ML
- Subjects
- Adult, Child, Humans, Infant, Amoxicillin adverse effects, Anti-Bacterial Agents adverse effects, Cephalosporins adverse effects, Chronic Disease, Macrolides adverse effects, Penicillins adverse effects, Randomized Controlled Trials as Topic, Recurrence, Streptococcus pyogenes, Systematic Reviews as Topic, Azithromycin adverse effects, Pharyngitis drug therapy
- Abstract
Background: Antibiotics provide only modest benefit in treating sore throat, although their effectiveness increases in people with positive throat swabs for group A beta-haemolytic streptococci (GABHS). It is unclear which antibiotic is the best choice if antibiotics are indicated. This is an update of a review first published in 2010, and updated in 2013, 2016, and 2021., Objectives: To assess the comparative efficacy of different antibiotics in: (a) alleviating symptoms (pain, fever); (b) shortening the duration of the illness; (c) preventing clinical relapse (i.e. recurrence of symptoms after initial resolution); and (d) preventing complications (suppurative complications, acute rheumatic fever, post-streptococcal glomerulonephritis). To assess the evidence on the comparative incidence of adverse effects and the risk-benefit of antibiotic treatment for streptococcal pharyngitis., Search Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2023, Issue 2), MEDLINE Ovid, Embase Elsevier, and Web of Science (Clarivate) up to 19 March 2023., Selection Criteria: Randomised, double-blind trials comparing different antibiotics, and reporting at least one of the following: clinical cure, clinical relapse, or complications and/or adverse events., Data Collection and Analysis: Two review authors independently screened trials for inclusion and extracted data using standard methodological procedures recommended by Cochrane. We assessed the risk of bias in the included studies according to the methods outlined in the Cochrane Handbook for Systematic Reviews of Interventions, and used the GRADE approach to assess the overall certainty of the evidence for the outcomes. We reported the intention-to-treat analysis, and also performed an analysis of evaluable participants to explore the robustness of the intention-to-treat results., Main Results: We included 19 trials reported in 18 publications (5839 randomised participants): six trials compared penicillin with cephalosporins; six compared penicillin with macrolides; three compared penicillin with carbacephem; one compared penicillin with sulphonamides; one compared clindamycin with ampicillin; and one compared azithromycin with amoxicillin in children. All participants had confirmed acute GABHS tonsillopharyngitis, and ages ranged from one month to 80 years. Nine trials included only, or predominantly, children. Most trials were conducted in an outpatient setting. Reporting of randomisation, allocation concealment, and blinding was poor in all trials. We downgraded the certainty of the evidence mainly due to lack of (or poor reporting of) randomisation or blinding, or both, heterogeneity, and wide confidence intervals. Cephalosporins versus penicillin We are uncertain if there is a difference in symptom resolution (at 2 to 15 days) for cephalosporins versus penicillin (odds ratio (OR) for absence of symptom resolution 0.79, 95% confidence interval (CI) 0.55 to 1.12; 5 trials, 2018 participants; low-certainty evidence). Results of the sensitivity analysis of evaluable participants differed (OR 0.51, 95% CI 0.27 to 0.97; 5 trials, 1660 participants; very low-certainty evidence). Based on an analysis of evaluable participants, we are uncertain if clinical relapse may be lower for cephalosporins compared with penicillin (OR 0.55, 95% CI 0.30 to 0.99; number needed to treat for an additional beneficial outcome (NNTB) 50; 4 trials, 1386 participants; low-certainty evidence). Very low-certainty evidence showed no difference in reported adverse events. Macrolides versus penicillin We are uncertain if there is a difference between macrolides and penicillin for resolution of symptoms (OR 1.11, 95% CI 0.92 to 1.35; 6 trials, 1728 participants; low-certainty evidence). Sensitivity analysis of evaluable participants resulted in an OR of 0.79 (95% CI 0.57 to 1.09; 6 trials, 1159 participants). We are uncertain if clinical relapse may be different (OR 1.21, 95% CI 0.48 to 3.03; 6 trials, 802 participants; low-certainty evidence). Children treated with macrolides seemed to experience more adverse events than those treated with penicillin (OR 2.33, 95% CI 1.06 to 5.15; 1 trial, 489 participants; low-certainty evidence). However, the test for subgroup differences between children and adults was not significant. Azithromycin versus amoxicillin Based on one unpublished trial in children, we are uncertain if resolution of symptoms is better with azithromycin in a single dose versus amoxicillin for 10 days (OR 0.76, 95% CI 0.55 to 1.05; 1 trial, 673 participants; very low-certainty evidence). Sensitivity analysis for per-protocol analysis resulted in an OR of 0.29 (95% CI 0.11 to 0.73; 1 trial, 482 participants; very low-certainty evidence). We are also uncertain if there was a difference in relapse between groups (OR 0.88, 95% CI 0.43 to 1.82; 1 trial, 422 participants; very low-certainty evidence). Adverse events were more common with azithromycin compared to amoxicillin (OR 2.67, 95% CI 1.78 to 3.99; 1 trial, 673 participants; very low-certainty evidence). Carbacephem versus penicillin There is low-certainty evidence that compared with penicillin, carbacephem may provide better symptom resolution post-treatment in adults and children (OR 0.70, 95% CI 0.49 to 0.99; NNTB 14.3; 3 trials, 795 participants). Studies did not report on long-term complications, so it was unclear if any class of antibiotics was better at preventing serious but rare complications., Authors' Conclusions: We are uncertain if there are clinically relevant differences in symptom resolution when comparing cephalosporins and macrolides with penicillin in the treatment of GABHS tonsillopharyngitis. Low-certainty evidence in children suggests that carbacephem may be more effective than penicillin for symptom resolution. There is insufficient evidence to draw conclusions regarding the other comparisons in this review. Data on complications were too scarce to draw conclusions. Antibiotics have a limited effect in the treatment of GABHS pharyngitis and the results do not demonstrate that other antibiotics are more effective than penicillin. In the context of antimicrobial stewardship, penicillin can be used if treatment with an antibiotic is indicated. All studies were conducted in high-income countries with a low risk of streptococcal complications, so there is a need for trials in low-income countries and disadvantaged populations, where the risk of complications remains high., (Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
31. Stevens-Johnson syndrome: a case report of possible cephalosporin-induced cutaneous adverse reaction.
- Author
-
Mkhoyan A, Hashmi MF, Khan F, Gyulazyan N, Asoyan V, and Nersisyan V
- Subjects
- Female, Humans, Middle Aged, Skin, Cephalosporins adverse effects, Stevens-Johnson Syndrome diagnosis, Stevens-Johnson Syndrome etiology, Stevens-Johnson Syndrome drug therapy, Communicable Diseases
- Abstract
A severe medical condition known as Stevens-Johnson syndrome (SJS) is marked by a cutaneous and mucosal reaction from the use of specific medications. The prodromal illness is followed by severe mucocutaneous symptoms in this immune-mediated disease. We describe the clinical history of a 55-year-old Caucasian woman who was exposed to cephalosporins. In resource-constrained countries and hospitals where cutaneous biopsy is not readily available, it is not easy to diagnose Steven Johnson Syndrome. This is particularly true in countries where the incidence of infectious diseases such as scarlet fever and measles is high and the early symptoms of SJS can be mistaken for these conditions. We used the Naronjo scale to confirm the probable association of the drug with the syndrome. Physicians while writing prescriptions for their patients need to warn them of potential side effects and they should keep in mind conditions like Stevens-Johnson syndrome. This case report highlights the need for improved knowledge and understanding of SJS among healthcare practitioners in resource-limited communities where the prevalence of infectious diseases is high., Competing Interests: No Conflict of Interest is declared, (Copyright (c) 2023 Anna Mkhoyan, Md. Foorquan Hashmi, Fiza Khan, Naira Gyulazyan, Vigen Asoyan, Varsen Nersisyan.)
- Published
- 2023
- Full Text
- View/download PDF
32. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia.
- Author
-
Torres A, Kuraieva A, Stone GG, and Cillóniz C
- Subjects
- Adult, Child, Humans, Linezolid, Vancomycin, Cephalosporins adverse effects, Anti-Bacterial Agents adverse effects, Ceftaroline, Methicillin-Resistant Staphylococcus aureus, Community-Acquired Infections diagnosis, Community-Acquired Infections drug therapy, Pneumonia, Ventilator-Associated diagnosis, Pneumonia, Ventilator-Associated drug therapy
- Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted coverage of suspected MRSA in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), are vancomycin and linezolid. However, adverse events such as acute kidney injury and Clostridium difficile infection have been associated with these antibiotics. Ceftaroline fosamil is a β-lactam/extended-spectrum cephalosporin approved for the treatment of adults and children with CAP and complicated skin and soft tissue infections. Ceftaroline has in vitro activity against a range of common Gram-positive bacteria and is distinct among the β-lactams in retaining activity against MRSA. Due to the design of the pivotal randomised controlled trials of ceftaroline fosamil, outcomes in patients with MRSA CAP were not evaluated. However, various reports of real-world outcomes with ceftaroline fosamil for pneumonia caused by MRSA, including CAP and HAP/VAP, been published since its approval. A systematic literature review and qualitative analysis of relevant publications was undertaken to collate and summarise relevant published data on the efficacy and safety of ceftaroline fosamil in patients with MRSA pneumonia. While relatively few real-world outcomes studies are available, the available data suggest that ceftaroline fosamil is a possible alternative to linezolid and vancomycin for MRSA pneumonia. Specific scenarios in which ceftaroline fosamil might be considered include bacteraemia and complicating factors such as empyema., Competing Interests: Conflict of interest: A. Torres has no conflicts of interest related to the current article. A. Kuraieva is an employee of Pfizer. G.G. Stone is an employee of Pfizer. C. Cillóniz has no conflicts of interest related to the current article., (Copyright ©The authors 2023.)
- Published
- 2023
- Full Text
- View/download PDF
33. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.
- Author
-
Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, and Fowler VG Jr
- Subjects
- Adult, Humans, Cephalosporins administration & dosage, Cephalosporins adverse effects, Cephalosporins therapeutic use, Methicillin-Resistant Staphylococcus aureus, Treatment Outcome, Double-Blind Method, Administration, Intravenous, Aztreonam administration & dosage, Aztreonam adverse effects, Aztreonam therapeutic use, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents therapeutic use, Bacteremia drug therapy, Bacteremia microbiology, Daptomycin administration & dosage, Daptomycin adverse effects, Daptomycin therapeutic use, Staphylococcal Infections drug therapy, Staphylococcal Infections microbiology, Staphylococcus aureus
- Abstract
Background: Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus ., Methods: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new S. aureus bacteremia-related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments. Safety was also assessed., Results: Of 390 patients who underwent randomization, 387 (189 in the ceftobiprole group and 198 in the daptomycin group) had confirmed S. aureus bacteremia and received ceftobiprole or daptomycin (modified intention-to-treat population). A total of 132 of 189 patients (69.8%) in the ceftobiprole group and 136 of 198 patients (68.7%) in the daptomycin group had overall treatment success (adjusted difference, 2.0 percentage points; 95% confidence interval [CI], -7.1 to 11.1). Findings appeared to be consistent between the ceftobiprole and daptomycin groups in key subgroups and with respect to secondary outcomes, including mortality (9.0% and 9.1%, respectively; 95% CI, -6.2 to 5.2) and the percentage of patients with microbiologic eradication (82.0% and 77.3%; 95% CI, -2.9 to 13.0). Adverse events were reported in 121 of 191 patients (63.4%) who received ceftobiprole and 117 of 198 patients (59.1%) who received daptomycin; serious adverse events were reported in 36 patients (18.8%) and 45 patients (22.7%), respectively. Gastrointestinal adverse events (primarily mild nausea) were more frequent with ceftobiprole., Conclusions: Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated S. aureus bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
34. Cephalosporins can be safely administered to patients with verified penicillin allergy.
- Author
-
Belmont AP, Su C, and Kwah J
- Subjects
- Humans, Cephalosporins adverse effects, Penicillins adverse effects, Anti-Bacterial Agents adverse effects, Skin Tests, Cross Reactions, Drug Hypersensitivity diagnosis, Drug Hypersensitivity drug therapy, Hypersensitivity drug therapy
- Published
- 2023
- Full Text
- View/download PDF
35. Association Between Fluoroquinolone Use and Hospitalization With Aortic Aneurysm or Aortic Dissection.
- Author
-
Brown JP, Wing K, Leyrat C, Evans SJ, Mansfield KE, Wong AYS, Smeeth L, Galwey NW, and Douglas IJ
- Subjects
- Adult, Humans, Female, Middle Aged, Aged, Male, Fluoroquinolones adverse effects, Cohort Studies, Cross-Over Studies, Anti-Bacterial Agents adverse effects, Cephalosporins adverse effects, Monobactams, Hospitalization, Aortic Aneurysm chemically induced, Aortic Aneurysm epidemiology, Aortic Dissection chemically induced, Aortic Dissection epidemiology
- Abstract
Importance: Fluoroquinolone use has been associated with increased hospitalization with aortic aneurysm or dissection in noninterventional studies, but the reason for this observed association is unclear., Objective: To determine the association between fluoroquinolone use and aortic aneurysm or dissection using multiple study designs and multiple databases to increase the robustness of findings., Design, Setting, and Participants: Cohort and case-crossover studies were conducted separately in 2 databases of UK primary care records. Clinical Practice Research Datalink Aurum and GOLD primary care records were linked to hospital admissions data. Adults with a systemic fluoroquinolone or cephalosporin prescription between April 1997 and December 2019 were included in the cohort study. Adults hospitalized with aortic aneurysm or dissection within the eligibility period were included in the case-crossover study. Individuals meeting inclusion criteria in the case-crossover study were matched 1:3 to control individuals on age, sex, index date, and clinical practice to adjust for calendar trends in prescribing. Data were analyzed from January to July 2022., Exposures: Systemic fluoroquinolone or comparator antibiotic., Main Outcomes and Measures: Hazard ratios (HRs) were estimated in the cohort study for the association between prescription of fluoroquinolones and hospitalization with aortic aneurysm or dissection using stabilized inverse probability of treatment-weighted Cox regression. Odds ratios (OR) were estimated in the case-crossover study for the association between systemic fluoroquinolone use and hospitalization with aortic aneurysm or dissection using a conditional logistic regression model. Estimates were pooled across databases using fixed-effects meta-analysis., Results: In the cohort study, we identified 3 134 121 adults in Aurum (mean [SD] age, 52.5 [20.3] years; 1 969 257 [62.8%] female) and 452 086 in GOLD (mean [SD] age, 53.9 [20.2] years; 286 502 [63.4%] female) who were prescribed fluoroquinolones or cephalosporins. In crude analyses, fluoroquinolone relative to cephalosporin use was associated with increased hospitalization with aortic aneurysm or dissection (pooled HR, 1.28; 95% CI, 1.13-1.44; P < .001) but after adjustment for potential confounders, this association disappeared (pooled adjusted HR, 1.03; 95% CI, 0.91-1.17; P = .65). In the case-crossover study, we identified 84 841 individuals hospitalized with aortic aneurysm or dissection in Aurum (mean [SD] age, 75.5 [10.9]; 23 551 [27.8%] female) and 10 357 in GOLD (mean [SD] age, 75.6 [10.5]; 2809 [27.1%] female). Relative to nonuse, fluoroquinolone use was associated with an increase in hospitalization with aortic aneurysm or dissection, but no association was found relative to other antibiotics (vs cephalosporin pooled OR, 1.05; 95% CI, 0.87-1.27; vs trimethoprim, 0.89; 95% CI, 0.75-1.06; vs co-amoxiclav, 0.98; 95% CI, 0.82-1.18)., Conclusions and Relevance: The results in this study suggest that estimates of association of fluoroquinolones with aortic aneurysm or dissection may be affected by confounding. When such confounding is accounted for, no association was evident, providing reassurance on the safety of fluoroquinolones with respect to aortic aneurysm or dissection.
- Published
- 2023
- Full Text
- View/download PDF
36. Impact of an Inpatient Allergy Guideline on β-Lactam and Alternative Antibiotic Use.
- Author
-
Otani IM, Tang M, Wang L, Anstey KM, Hilts-Horeczko A, Li F, Le VP, Lee M, Bystritsky R, Mulliken JS, Wattier RL, Blumenthal KG, and Doernberg SB
- Subjects
- Humans, Anti-Bacterial Agents adverse effects, beta-Lactams adverse effects, Inpatients, Aztreonam, Penicillins adverse effects, Cephalosporins therapeutic use, Cephalosporins adverse effects, Retrospective Studies, Drug Hypersensitivity drug therapy, Hypersensitivity drug therapy
- Abstract
Background: A guideline identifying when inpatients with penicillin or cephalosporin antibiotic allergy labels (PCAAL) can receive β-lactam antibiotics increased β-lactam receipt at a large northeastern US health care system., Objective: To report outcomes of implementing a similar guideline and electronic order set (OS) at an independent academic health care system., Methods: Penicillin/cephalosporin receipt (percentage of inpatients receiving full doses) and alternative antibiotic use (days of therapy per 1000 patient-days [DOT/1000PD]) were compared over 3 periods before (February 1, 2017, to January 31, 2018) and after guideline implementation (February 1, 2018, to January 31, 2019), and after OS implementation (February 1, 2019, to January 31, 2020) among inpatients with PCAAL admitted on medical services with access to guideline/OS and education (Medical-PCAAL, n = 8721), surgical services with access to guideline/OS without education (Surgical-PCAAL, n = 5069), and obstetrics/gynecology services without interventions (Ob/Gyn-PCAAL, n = 798) and inpatients without PCAAL admitted on the same services (Medical-No-PCAAL, n = 50,840; Surgical-No-PCAAL, n = 29,845; Ob/Gyn-No-PCAAL, n = 6109). χ
2 tests were used to compare categorical variables, and analysis of variance was used to compare continuous and interrupted time series analyses (ITSA) to investigate the guideline/OS implementation effect on penicillin/cephalosporin receipt., Results: In the Medical-PCAAL group, penicillin/cephalosporin receipt increased (58%-68%, P < .001), specifically for cefazolin (8%-11%, P = .02) and third- to fifth-generation cephalosporins (43%-48%, P = .04), and aztreonam use decreased (12 DOT/1000PD, P = .03). In the Medical-No-PCAAL group, penicillin/cephalosporin receipt increased (88%-90%, P = .004), specifically for penicillin (40%-44%, P < .001), without changes in aztreonam use. Significant changes were not observed in these outcomes on surgical or obstetrics/gynecology services. Per ITSA, guideline/OS implementation was associated with increased penicillin/cephalosporin receipt in the Medical-PCAAL group only., Conclusion: Guideline and OS implementation was associated with improved antibiotic stewardship on inpatient services that also received allergy education., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
37. Nephrotoxicity of Amoxicillin and Third-Generation Cephalosporins: An Updated Review.
- Author
-
Garnier AS, Drablier G, Briet M, and Augusto JF
- Subjects
- Humans, Amoxicillin adverse effects, Kidney, Cephalosporins adverse effects, Anti-Bacterial Agents adverse effects, Drug-Related Side Effects and Adverse Reactions, Nephritis, Interstitial chemically induced, Nephritis, Interstitial drug therapy
- Abstract
Because of their broad-spectrum bactericidal activity, amoxicillin (AMX) and third-generation cephalosporins (TGC) are widely used for the prophylaxis and treatment of established infections. They are considered relatively safe, but several recent reports have suggested substantial nephrotoxicity, especially with AMX use. Considering the importance of AMX and TGC for clinical practice, we conducted this up-to-date review, using the PubMed database, which focuses specifically on the nephrotoxicity of these molecules. We also briefly review the pharmacology of AMX and TGC. Nephrotoxicity of AMX may be driven by several pathophysiological mechanisms, such as a type IV hypersensitivity reaction, anaphylaxis, or intratubular and/or urinary tract drug precipitation. In this review, we focused on the two main renal adverse effects of AMX, namely acute interstitial nephritis and crystal nephropathy. We summarize the current knowledge in terms of incidence, pathogenesis, factors, clinical features, and diagnosis. The purpose of this review is also to underline the probable underestimation of AMX nephrotoxicity and to educate clinicians about the recent increased incidence and severe renal prognosis associated with crystal nephropathy. We also suggest some key elements on the management of these complications to avoid inappropriate use and to limit the risk of nephrotoxicity. While renal injury appears to be rarer with TGC, several patterns of nephrotoxicity have been reported in the literature, such as nephrolithiasis, immune-mediated hemolytic anemia, or acute interstitial nephropathy, which we detail in the second part of this review., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF
38. The safety of ceftolozane/tazobactam for the treatment of complicated urinary tract infections.
- Author
-
Bassetti M, Vena A, and Giacobbe DR
- Subjects
- Humans, Tazobactam adverse effects, Cephalosporins adverse effects, Carbapenems, Anti-Bacterial Agents adverse effects, Urinary Tract Infections drug therapy, Urinary Tract Infections chemically induced
- Abstract
Introduction: Ceftolozane is a cephalosporin similar to ceftazidime in its structure, which is marketed in combination with tazobactam, a well-known β-lactamase inhibitor., Areas Covered: After a brief introduction on the drug characteristics and efficacy, we focused on available data from randomized controlled trials and post-marketing observational studies pertaining to the safety of ceftolozane/tazobactam (C/T) for the treatment of complicated urinary tract infections (cUTI). A search was conducted in PubMed from January 2010 to February 2023., Expert Opinion: The use of C/T for the treatment of cUTI is supported by solid efficacy and safety data, especially for the treatment of those pathogens where it can represent a first-line approach due to some peculiar characteristics: (i) treatment of cUTI caused by multidrug-resistant Pseudomonas aeruginosa , in view of its frequent activity against carbapenem-resistant isolates when resistance mechanisms other than production of carbapenemases are concerned; (ii) treatment of cUTI caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacterales in those settings where the selective pressure for carbapenem resistance needs to be relieved, as a suitable and effective carbapenem-sparing option. Although development of resistance to C/T during or after treatment has been reported, this has been reported very rarely in patients receiving C/T for the treatment of cUTI.
- Published
- 2023
- Full Text
- View/download PDF
39. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
- Author
-
Jackson CA, Newland J, Dementieva N, Lonchar J, Su FH, Huntington JA, Bensaci M, Popejoy MW, Johnson MG, De Anda C, Rhee EG, and Bruno CJ
- Subjects
- Adult, Humans, Child, Meropenem adverse effects, Anti-Bacterial Agents adverse effects, Penicillanic Acid adverse effects, Cephalosporins adverse effects, Tazobactam adverse effects, Escherichia coli, Metronidazole adverse effects, Intraabdominal Infections drug therapy
- Abstract
Background: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination, is approved for the treatment of complicated urinary tract infections and complicated intra-abdominal infections (cIAI). The safety and efficacy of ceftolozane/tazobactam in pediatric participants with cIAI were assessed., Methods: This phase 2 study (NCT03217136) randomized participants to either ceftolozane/tazobactam+metronidazole or meropenem for treatment of cIAI in pediatric participants (<18 years). The primary objective was to assess the safety and tolerability of intravenous ceftolozane/tazobactam+metronidazole. Clinical cure at end of treatment (EOT) and test of cure (TOC) visits were secondary end points., Results: The modified intent-to-treat (MITT) population included 91 participants (ceftolozane/tazobactam+metronidazole, n = 70; meropenem, n = 21). Complicated appendicitis was the most common diagnosis (93.4%); Escherichia coli was the most common pathogen (65.9%). Adverse events (AEs) occurred in 80.0% and 61.9% of participants receiving ceftolozane/tazobactam+metronidazole and meropenem, drug-related AEs occurred in 18.6% and 14.3% and serious AEs occurred in 11.4% and 0% of participants receiving ceftolozane/tazobactam+metronidazole and meropenem, respectively. No drug-related serious AEs or discontinuations due to drug-related AEs occurred. Rates of the clinical cure for ceftolozane/tazobactam+metronidazole and meropenem at EOT were 80.0% and 95.2% (difference: -14.3; 95% confidence interval: -26.67 to 4.93) and at TOC were 80.0% and 100.0% (difference: -19.1; 95% confidence interval: -30.18 to -2.89), respectively; 6 of the 14 clinical failures for ceftolozane/tazobactam+metronidazole at TOC were indeterminate responses imputed as failures per protocol., Conclusion: Ceftolozane/tazobactam+metronidazole was well tolerated in pediatric participants with cIAI and had a safety profile similar to the established safety profile in adults. In this descriptive efficacy analysis, ceftolozane/tazobactam+metronidazole appeared efficacious., Competing Interests: J.L., F.-H.S, J.A.H., M.B., M.G.J., C.D.A., E.G.R., and C.J.B. are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), who may own stock and/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. M.W.P. was an employee of MSD at the time of the study conduct. C.-C.A.J. received consulting fees from MSD and holds stock in Merck & Co., Inc., Rahway, NJ, USA. J.N. reports funding to conduct the study from MSD to his institution. N.D. has no potential conflicts of interest to disclose., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
40. The state and consideration for skin test of β-lactam antibiotics in pediatrics.
- Author
-
Gao C, Ma B, Liu W, and Zhu L
- Subjects
- Adult, Child, Humans, Skin Tests, Anti-Bacterial Agents adverse effects, beta-Lactams adverse effects, Penicillins adverse effects, Monobactams, Cephalosporins adverse effects, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Anaphylaxis, Pediatrics
- Abstract
β-lactam antibiotics are the most frequently used drugs and the most common drugs that cause allergic reactions in pediatrics. The occurrence of some allergic reactions can be predicted by skin testing, especially severe adverse reactions such as anaphylactic shock. Thus, penicillin and cephalosporin skin tests are widely used to predict allergic reactions before medication in pediatrics. However, false-positive results from skin tests were more often encountered in pediatrics than in adults. In fact, many children labeled as allergic to β-lactam are not allergic to the antibiotic, leading to the use of alternative antibiotics, which are less effective and more toxic, and the increase of antibiotic resistance. There has been controversy over whether β-lactam antibiotics should be tested for skin allergies before application in children. Based on the great controversy in the implementation of β-lactam antibiotic skin tests, especially the controversial cephalosporin skin tests in pediatrics, the mechanism and reasons of anaphylaxis to β-lactam antibiotics, the significance of β-lactam antibiotic skin tests, the current state of β-lactam antibiotic skin tests at home and abroad, and the problems of domestic and international skin tests were analyzed to determine a unified standard of β-lactam antibiotic skin tests in pediatrics to prevent and decrease adverse drug reactions, avoid waste of drugs, and a large amount of manpower and material resource consumption., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Gao, Ma, Liu and Zhu.)
- Published
- 2023
- Full Text
- View/download PDF
41. Multiple allergy to cephalosporins confirmed by patch test: From the first to the fifth generation.
- Author
-
Marietti R, Bianchi L, Hansel K, Casciola G, Biondi F, Tramontana M, and Stingeni L
- Subjects
- Humans, Cephalosporins adverse effects, Patch Tests, Anti-Bacterial Agents adverse effects, Skin Tests, Cross Reactions, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact etiology, Dermatitis, Allergic Contact drug therapy, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology
- Published
- 2023
- Full Text
- View/download PDF
42. Inaccurate penicillin allergy labels: Consequences, solutions, and opportunities for rhinologists.
- Author
-
Liu MY, McCoul ED, Brooks EG, Lao VF, and Chen PG
- Subjects
- Humans, Penicillins adverse effects, Anti-Bacterial Agents adverse effects, Cephalosporins adverse effects, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Drug Hypersensitivity therapy, Hypersensitivity
- Abstract
A patient-reported history of penicillin allergy is a common label with a prevalence of about 10%. However, as many as 95% of patients reporting a penicillin allergy do not have a true immunoglobin-E (IgE)-mediated allergic reaction. Unfortunately, penicillin allergy mislabeling is problematic, leading to inappropriate antibiotic use and negative consequences, such as adverse drug events, suboptimal outcomes, and increased costs. As physicians who treat patients of all ages for common sinonasal pathology in the clinic and operating room in addition to frequently providing testing and management of allergic diseases, rhinologists are well positioned to aid in delabeling patients with inaccurate penicillin allergies. This viewpoint highlights the consequences of inaccurate penicillin allergy designation in the clinic and perioperative period and explores misconceptions regarding cross-reactivity between penicillins and cephalosporins. Opportunities are explored for shared decision-making with colleagues in other specialties, such as anesthesiology, and practical recommendations are provided to aid rhinologists when faced with a patient who holds a questionable history of penicillin allergy. Rhinologists can play an active role in delabeling patients with inaccurate penicillin allergies with the goal of ensuring appropriate antibiotic use for future medical encounters., (© 2023 ARS-AAOA, LLC.)
- Published
- 2023
- Full Text
- View/download PDF
43. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
- Author
-
Roilides E, Ashouri N, Bradley JS, Johnson MG, Lonchar J, Su FH, Huntington JA, Popejoy MW, Bensaci M, De Anda C, Rhee EG, and Bruno CJ
- Subjects
- Adult, Infant, Newborn, Humans, Child, Meropenem adverse effects, Escherichia coli, Penicillanic Acid adverse effects, Cephalosporins adverse effects, Tazobactam adverse effects, Anti-Bacterial Agents adverse effects, Urinary Tract Infections drug therapy, Pyelonephritis drug therapy
- Abstract
Background: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination, active against multidrug-resistant Gram-negative pathogens, is approved for treatment of adults with complicated urinary tract infections (cUTI). Safety and efficacy of ceftolozane/tazobactam in pediatric participants with cUTI, including pyelonephritis, were assessed., Methods: This phase 2 study (NCT03230838) compared ceftolozane/tazobactam with meropenem for treatment of cUTI in participants from birth to <18 years of age. The primary objective was safety and tolerability. Key secondary end points included clinical cure and per-participant microbiologic response rates at end of treatment (EOT) and test of cure (TOC) visits., Results: The microbiologic modified intent-to-treat (mMITT) population included 95 participants (ceftolozane/tazobactam, n = 71; meropenem, n = 24). The most common diagnosis and pathogen were pyelonephritis (ceftolozane/tazobactam, 84.5%; meropenem, 79.2%) and Escherichia coli (ceftolozane/tazobactam, 74.6%; meropenem, 87.5%); 5.7% (ceftolozane/tazobactam) and 4.8% (meropenem) of E. coli isolates were extended-spectrum β-lactamase-producers. Rates of adverse events were similar between treatment groups (any: ceftolozane/tazobactam, 59.0% vs. meropenem, 60.6%; drug-related: ceftolozane/tazobactam, 14.0% vs. meropenem, 15.2%; serious: ceftolozane/tazobactam, 3.0% vs. meropenem, 6.1%). Rates of clinical cure for ceftolozane/tazobactam and meropenem at EOT were 94.4% and 100% and at TOC were 88.7% and 95.8%, respectively. Rates of microbiologic eradication for ceftolozane/tazobactam and meropenem at EOT were 93.0% and 95.8%, and at TOC were 84.5% and 87.5%, respectively., Conclusions: Ceftolozane/tazobactam had a favorable safety profile in pediatric participants with cUTI; rates of clinical cure and microbiologic eradication were high and similar to meropenem. Ceftolozane/tazobactam is a safe and effective new treatment option for children with cUTI, especially due to antibacterial-resistant Gram-negative pathogens., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
44. Antibiotic associated diarrhea in outpatient pediatric antibiotic therapy.
- Author
-
Tanır Basaranoğlu S, Karaaslan A, Salı E, Çiftçi E, Gayretli Aydın ZG, Aldemir Kocabaş B, Kaya C, Şen Bayturan S, Kara SS, Yılmaz Çiftdoğan D, Çay Ü, Gundogdu Aktürk H, Çelik M, Ozdemir H, Somer A, Diri T, Yazar AS, Sütçü M, Tezer H, Karadag Oncel E, Kara M, Çelebi S, Özkaya Parlakay A, Karakaşlılar S, Arısoy ES, Tanır G, Tural Kara T, Devrim İ, Erat T, Aykaç K, Kaba Ö, Güven Ş, Yeşil E, Tekin Yılmaz A, Yaşar Durmuş S, Çağlar İ, Günay F, Özen M, Dinleyici EÇ, and Kara A
- Subjects
- Child, Humans, Prospective Studies, Amoxicillin-Potassium Clavulanate Combination adverse effects, Cephalosporins adverse effects, Diarrhea chemically induced, Diarrhea epidemiology, Diarrhea drug therapy, Outpatients, Anti-Bacterial Agents adverse effects
- Abstract
Background: Antibiotic-associated diarrhea is one of the most frequent side effects of antimicrobial therapy. We assessed the epidemiological data of antibiotic-associated diarrhea in pediatric patients in our region., Methods: The prospective multi-center study included pediatric patients who were initiated an oral antibiotic course in outpatient clinics and followed in a well-established surveillance system. This follow-up system constituded inclusion of patient by the primary physician, supply of family follow-up charts to the family, passing the demographics and clinical information of patient to the Primary Investigator Centre, and a close telephone follow-up of patients for a period of eight weeks by the Primary Investigator Centre., Results: A result of 758 cases were recruited in the analysis which had a frequency of 10.4% antibiotic-associated diarrhea. Among the cases treated with amoxicillin-clavulanate 10.4%, and cephalosporins 14.4% presented with antibiotic-associated diarrhea. In the analysis of antibiotic-associated diarrhea occurrence according to different geographical regions of Turkey, antibiotic-associated diarrhea episodes differed significantly (p = 0.014), particularly higher in The Eastern Anatolia and Southeastern Anatolia. Though most commonly encountered with cephalosporin use, antibiotic-associated diarrhea is not a frequent side effect., Conclusion: This study on pediatric antibiotic-associated diarrhea displayed epidemiological data and the differences geographically in our region., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
45. [Clinical experience using cefiderocol].
- Author
-
Witzke O and Brenner T
- Subjects
- Adult, Humans, Monobactams, Carbapenems, Cefiderocol, Cephalosporins adverse effects, Anti-Bacterial Agents adverse effects
- Abstract
Background: Infections due to antibiotic-resistant bacteria are threatening modern healthcare, and antibacterial resistance has become one of the greatest threats to public health. In Germany 54,500 patients become infected with antibiotic-resistant bacteria per year, causing about 2400 attributable deaths. Rising resistance in Gram-negative bacteria especially carbapenem-resistant pathogens is of particular concern due to the lack of effective and safe alternative treatment options., Objective: The results from trials and compassionate-use programs with the new antibiotic cefiderocol, which was approved by the European Medicines Agency (EMA) in April 2020 for the treatment of adults with infections caused by aerobic Gram-negative bacteria, are summarized., Results: The new β‑lactam antibiotic cefiderocol is the first siderophore cephalosporin indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Its chemical structure and its unique mechanism of action confer enhanced stability against β‑lactamases including all classes of clinically relevant carbapenemases. In vitro data show high antibacterial activity against multidrug resistant Gram-negative bacteria, Enterobacterales and nonfermenters, including carbapenem-resistant strains. In clinical trials, cefiderocol showed superiority in complicated urinary tract infection in comparison to imipenem and non-inferiority versus meropenem in hospital-acquired/ventilator-associated pneumonia patients and severe infections caused by carbapenem-resistant pathogens., Conclusion: Clinical trial data and case reports identified in the literature search show that cefiderocol is a promising treatment option for severe infections caused by drug-resistant Gram-negative bacteria, particularly carbapenem-resistant bacteria., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
46. [What is new … cefiderocol].
- Author
-
Mehringer L, Seybold U, and Zoller M
- Subjects
- Cefiderocol, Cephalosporins adverse effects, Anti-Bacterial Agents adverse effects
- Published
- 2023
- Full Text
- View/download PDF
47. Outcome of preoperative cefazolin use for infection prophylaxis in patients with self-reported penicillin allergy.
- Author
-
Michaud L, Yen HH, Engen DA, and Yen D
- Subjects
- Humans, Cefazolin therapeutic use, Self Report, Surgical Wound Infection prevention & control, Surgical Wound Infection drug therapy, Retrospective Studies, Penicillins adverse effects, Anti-Bacterial Agents therapeutic use, Cephalosporins adverse effects, Antibiotic Prophylaxis, Drug Hypersensitivity drug therapy, Hypersensitivity drug therapy
- Abstract
Background: Cephalosporins are the preferred antibiotics for prophylaxis against surgical site infections. Most studies give a rate of combined IgE and non-IgE penicillin allergy yet it is recommended that cephalosporins be avoided in patients having the former but can be used in those with the latter. Some studies use penicillin allergy while others penicillin family allergy rates. The primary goal of this study was to determine the rates of IgE and non-IgE allergy as well as cross reactions to both penicillin and the penicillin family. Secondary goals were to determine the surgical services giving preoperative cefazolin and the types of self reported reactions that patients' had to penicillin prompting their allergy status., Methods: All patients undergoing elective and emergency surgery at a University Health Sciences Centre were retrospectively studied. The hospital electronic medical record was used for data collection., Results: 8.9% of our patients reported non-IgE reactions to penicillin with a cross reactivity rate of 0.9% with cefazolin. 4.0% of our patients reported IgE reactions to penicillin with a cross reactivity rate of 4.0% with cefazolin. 10.5% of our patients reported non-IgE reactions to the penicillin family with a cross reactivity rate of 0.8% with cefazolin. 4.3% of our patients reported IgE reactions to the penicillin family with a cross reactivity rate of 4.0% with cefazolin., Conclusions: Our rate of combined IgE and non-IgE reactions for both penicillin and penicillin family allergy was within the range reported in the literature. Our rate of cross reactivity between cefazolin and combined IgE and non-IgE allergy both to penicillin and the penicillin family were lower than reported in the old literature but within the range of the newer literature. We found a lower rate of allergic reaction to a cephalosporin than reported in the literature. We documented a wide range of IgE and non-IgE reactions. We also demonstrated that cefazolin is frequently the preferred antibiotics for prophylaxis against surgical site infections by many surgical services and that de-labelling patients with penicillin allergy is unnecessary., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
48. Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
- Author
-
Karruli A, Massa A, Andini R, Marrazzo T, Ruocco G, Zampino R, and Durante-Mangoni E
- Subjects
- Humans, Aged, Retrospective Studies, Cephalosporins adverse effects, Gram-Negative Bacteria, Treatment Outcome, Microbial Sensitivity Tests, Cefiderocol, Anti-Bacterial Agents adverse effects, Drug Resistance, Multiple, Bacterial
- Abstract
Objectives: Cefiderocol is a 'siderophore' cephalosporin active against Gram-negative bacteria, including carbapenem-resistant strains. Data on the use of cefiderocol in real life are limited. We evaluated the efficacy and safety of cefiderocol in the context of our hospital clinical practice., Methods: This was a single-centre, observational, retrospective clinical study. We collected data for all patients who received cefiderocol therapy in our hospital, with a focus on clinical outcomes and adverse events., Results: The study cohort included 28 patients, with a median age of 73 years (25-83 years) and a high burden of co-morbidities. Up to 45 Gram-negative isolates were cultured from the study patients, the most common pathogen being Acinetobacter baumannii (31.1%). Cefiderocol was mostly prescribed for pneumonia (37.8% of cases), bloodstream infection (24.4%), urinary tract infection (22.2%) and intra-abdominal infection (20%), and largely as salvage therapy (92.8%). Of the 18 patients for whom follow-up cultures were available, 14 (77.8%) achieved eradication of the causative micro-organism. Therapeutic success (improvement/resolution of infection) occurred in 64.3% of cases at 7 days and 50% at 14 days from treatment start. Treatment failed in 9 cases (32.1%). No effects on kidney, liver or bone marrow function were observed., Conclusions: Cefiderocol showed fair efficacy and excellent tolerability in highly co-morbid patients with a range of multiresistant infections. It may be an option for infections due to colistin-resistant pathogens, when other regimens fail or in cases at risk of kidney dysfunction., (Copyright © 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
49. Emergent "Bloody Diarrhea" Associated with the Use of Oral Cefdinir in Young Children: A Brief Report and Review of Literature.
- Author
-
Al Okla S, Prashanth GP, Kurbet S, Al Attraqchi Y, and Asaad A
- Subjects
- Infant, Child, Humans, Child, Preschool, Cefdinir, Anti-Bacterial Agents therapeutic use, Cephalosporins adverse effects, Iron, Bacterial Infections, Drug-Related Side Effects and Adverse Reactions
- Abstract
Background: Cefdinir is an extended-spectrum, third-generation, oral cephalosporin widely used in pediatric population to treat common bacterial infections, including otitis media and streptococcal pharyngitis. It is considered a safe and well-tolerated alternative to penicillin and macrolides., Case Report: This report describes a case series of 3 infants presenting to the emergency department for evaluation of "bloody diarrhea." The parents noticed red stools when their children were started on oral cefdinir when they were previously receiving iron-containing preparations. Reddish-colored heme-negative stools observed in all cases were due to the interaction of the drug with supplemental iron or iron-containing formula feeds. This adverse effect was reversible on discontinuation of cefdinir. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Red stools due to cefdinir is an underreported benign adverse drug reaction with fewer than 10 cases described in the literature. Thorough history taking with an appropriate focus on diet and drug history are essential to avoid parental anxiety, unnecessary patient workup, and economic burden to the caregivers in these cases. Awareness of this unusual adverse effect among emergency physicians could prevent further inconvenience for already overburdened health systems., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
50. The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies.
- Author
-
Chi Y, Xu J, Bai N, Liang B, and Cai Y
- Subjects
- Adult, Humans, Aminoglycosides, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents therapeutic use, Gram-Negative Bacteria, Microbial Sensitivity Tests, Monobactams, Polymyxins, Pseudomonas aeruginosa, Cephalosporins adverse effects, Cephalosporins therapeutic use, Gram-Negative Bacterial Infections drug therapy, Pseudomonas Infections drug therapy, Tazobactam adverse effects, Tazobactam therapeutic use
- Abstract
Background: Ceftolozane-tazobactam is a novel cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacteria (GNB). We aimed to comprehensively evaluate the clinical efficacy and safety of ceftolozane-tazobactam in treating GNB infections in adult patients., Research Design and Methods: PubMed, Embase, and Cochrane databases were retrieved until August 2022. Randomized trials and non-randomized controlled studies evaluating ceftolozane-tazobactam and its comparators in adult patients with GNB infections were included., Results: A total of 13 studies were included. Overall, patients receiving ceftolozane-tazobactam had significant advantages in clinical cure (odds ratio [OR], 1.62; 95% CI, 1.05-2.51) and microbiological eradication (OR, 1.43; 95% CI, 1.19-1.71), especially in Pseudomonas aeruginosa -infected patients. Ceftolozane-tazobactam had a significant advantage in clinical success or microbial eradication compared with polymyxin/aminoglycosides (PL/AG) or levofloxacin. There were no significant differences in adverse events (AEs), Clostridium difficile infection (CDI), and mortality between ceftolozane-tazobactam and comparators. Notably, ceftolozane-tazobactam showed a significantly lower risk of acute kidney injury compared with PL/AG., Conclusions: Ceftolozane-tazobactam showed excellent clinical and microbiological efficacy in treating GNB, especially P. aeruginosa -induced infections. The overall safety profile of ceftolozane-tazobactam was comparable to other antimicrobials, with no increased risk of CDI and obvious advantage over antibacterial agents with high nephrotoxicity.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.